Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies?
immunotherapy
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
accepted:
29
04
2020
entrez:
1
6
2020
pubmed:
1
6
2020
medline:
29
7
2021
Statut:
ppublish
Résumé
Recently, an increasing number of novel drugs were approved in oncology and hematology. Nevertheless, pharmacology progress comes with a variety of side effects, of which cytokine release syndrome (CRS) is a potential complication of some immunotherapies that can lead to multiorgan failure if not diagnosed and treated accordingly. CRS generally occurs with therapies that lead to highly activated T cells, like chimeric antigen receptor T cells or in the case of bispecific T-cell engaging antibodies. This, in turn, leads to a proinflammatory state with subsequent organ damage. To better manage CRS there is a need for specific therapies or to repurpose strategies that are already known to be useful in similar situations. Current management strategies for CRS are represented by anticytokine directed therapies and corticosteroids. Based on its pathophysiology and the resemblance of CRS to sepsis and septic shock, as well as based on the principles of initiation of continuous renal replacement therapy (CRRT) in sepsis, we propose the rationale of using CRRT therapy as an adjunct treatment in CRS where all the other approaches have failed in controlling the clinically significant manifestations.
Identifiants
pubmed: 32474415
pii: jitc-2020-000742
doi: 10.1136/jitc-2020-000742
pmc: PMC7264828
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Clin Cancer Res. 2019 Jan 1;25(1):29-34
pubmed: 30322878
J Immunother Cancer. 2018 Jun 15;6(1):56
pubmed: 29907163
Ther Clin Risk Manag. 2019 Feb 28;15:323-335
pubmed: 30880998
Nephron Clin Pract. 2010;115(1):c1-6
pubmed: 20173343
Blood. 2013 Jun 27;121(26):5154-7
pubmed: 23678006
Kidney Int Suppl. 1999 Nov;(72):S56-61
pubmed: 10560807
Biol Blood Marrow Transplant. 2020 Jun;26(6):1071-1076
pubmed: 32088364
Blood. 2014 Jul 10;124(2):188-95
pubmed: 24876563
Int J Biol Sci. 2012;8(9):1237-47
pubmed: 23136552
Crit Care Med. 2017 Feb;45(2):e124-e131
pubmed: 27632680
J Transl Int Med. 2018 Jun 26;6(2):62-65
pubmed: 29984198
Sci Transl Med. 2014 Feb 19;6(224):224ra25
pubmed: 24553386
N Engl J Med. 2017 Mar 2;376(9):836-847
pubmed: 28249141
Intensive Care Med. 1993;19(6):329-32
pubmed: 8227722
Anesthesiology. 2012 Jun;116(6):1377-87
pubmed: 22534247
N Engl J Med. 2014 Oct 16;371(16):1507-17
pubmed: 25317870
Drugs. 2018 Jun;78(9):929-940
pubmed: 29931592
Rom J Intern Med. 2016 Sep 1;54(3):194-200
pubmed: 27658169
Cancer J. 2014 Mar-Apr;20(2):119-22
pubmed: 24667956
Am J Kidney Dis. 2020 Jan 20;:
pubmed: 31973908
Med Ultrason. 2017 Mar 14;19(3):330-332
pubmed: 28845502
Nephrourol Mon. 2013 Sep;5(4):891-6
pubmed: 24350088
PLoS One. 2017 Oct 30;12(10):e0187015
pubmed: 29084247
Ther Clin Risk Manag. 2005 Jun;1(2):141-50
pubmed: 18360553
Biol Blood Marrow Transplant. 2016 Mar;22(3):493-8
pubmed: 26497906
Expert Rev Clin Immunol. 2019 Aug;15(8):813-822
pubmed: 31219357
Ann Rheum Dis. 2019 Apr;78(4):456-464
pubmed: 30679153
Biol Blood Marrow Transplant. 2019 Apr;25(4):e123-e127
pubmed: 30586620
Intensive Care Med Exp. 2018 May 4;6(1):12
pubmed: 29728790
Immunotherapy. 2016 Jul;8(8):959-70
pubmed: 27381687
Blood Purif. 2018;46(4):337-349
pubmed: 30176653
Oncotarget. 2017 Feb 7;8(6):10628-10636
pubmed: 27833089
N Engl J Med. 2009 Oct 22;361(17):1627-38
pubmed: 19846848
EXCLI J. 2013 Aug 12;12:681-92
pubmed: 26600735
Crit Care. 2013 Mar 26;17(2):R59
pubmed: 23531333
Intensive Care Med. 2013 Sep;39(9):1535-46
pubmed: 23740278
Crit Care Med. 1999 Oct;27(10):2096-104
pubmed: 10548188
Mol Ther Oncolytics. 2016 Apr 20;3:16011
pubmed: 27626062
Front Immunol. 2018 Feb 19;9:239
pubmed: 29515572
Front Oncol. 2019 Sep 10;9:892
pubmed: 31552193
Nat Immunol. 2015 May;16(5):448-57
pubmed: 25898198
J Clin Med. 2019 Aug 06;8(8):
pubmed: 31390838
Lancet Oncol. 2015 Jan;16(1):57-66
pubmed: 25524800
Semin Dial. 2009 Mar-Apr;22(2):141-5
pubmed: 19426417
Cancer. 2016 Jul 15;122(14):2178-85
pubmed: 27143254
Eur J Immunol. 1993 Sep;23(9):2209-16
pubmed: 8370401
Cancer. 2016 Nov 15;122(21):3316-3326
pubmed: 27404668
Cancer Med. 2018 Apr 13;:
pubmed: 29654631
J Artif Organs. 2017 Dec;20(4):335-340
pubmed: 28894963
J Clin Med. 2019 Jun 20;8(6):
pubmed: 31226876
Oncotarget. 2017 Dec 15;9(1):1483-1491
pubmed: 29416707
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638
pubmed: 30592986
J Immunol Methods. 2016 Jul;434:1-8
pubmed: 27049586
J Immunother. 2018 Nov/Dec;41(9):406-410
pubmed: 30198955
Int J Artif Organs. 2006 Sep;29(9):819-22
pubmed: 17033987
Acta Haematol. 2016;135(4):211-6
pubmed: 26914538
Chest. 2019 Mar;155(3):626-638
pubmed: 30266628
Immunotargets Ther. 2019 Oct 29;8:43-52
pubmed: 31754614
Blood. 2016 Jun 30;127(26):3321-30
pubmed: 27207799
N Engl J Med. 2013 Apr 18;368(16):1509-1518
pubmed: 23527958
Curr Opin Crit Care. 2018 Dec;24(6):476-482
pubmed: 30308541
Nat Med. 2018 Jun;24(6):739-748
pubmed: 29808007
Crit Care Med. 2008 Jan;36(1):268-72
pubmed: 18090355
Crit Care. 2018 Oct 25;22(1):262
pubmed: 30360755
Am J Kidney Dis. 1986 Sep;8(3):196-201
pubmed: 3752075